Nile Pharmaceuticals results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit90.23 millionEGP · −24.3% vs the same period a year earlier
Total assets1.47 billionEGP · +41.9% vs the same period a year earlier
Shareholders' equity469 millionEGP · −2.0% vs the same period a year earlier
Operating cash flow264 millionEGP · +733.0% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q4 2024 was about 90.23 million EGP, down −24.3% from 119 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 1.47 billion EGP, and shareholders' equity about 469 million EGP.
- Operating cash flow for Q4 2024 was positive at 264 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit90.23 million119 million−24.3%
Gross profit298 million595 million−49.9%
Total assets1.47 billion1.04 billion+41.9%
Total liabilities1 billion560 million+79.4%
Shareholders' equity469 million478 million−2.0%
Total liabilities and equity1.47 billion1.04 billion+41.9%
Operating cash flow264 million-41.73 million+733.0%
Investing cash flow-420 million-27.52 million−1424.8%
Financing cash flow303 million273 million+11.3%
Net change in cash-121 million-11.38 million−962.7%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy